Being A Biosimilar Product, It Will Take Some Time Before The Competing Medications Become Marketable Products That May Subtract From Abbvie’s Humira Market Share.

The company closed its third quarter reporting Humira sales of $4,060, +11.3% on a year over year basis and -2.2% from the previous quarter of 2016. In the third quarter of 2016, the sale of Humira represented approximately 63.6% of AbbVie’s total adjusted net revenues. no dataThe medication, introduced to the market in January 2003, is approved for use in North America, the European Union and is also approved for more than 60 other markets, including Japan, China, Brazil and Australia. Since the patent covering adalimumab (brand name Humira), the human monoclonal antibody that recognizes TNF-alpha as antigen, is expected to expire in the U.S. in December 2016 and in the majority of EU countries in October 2018, investors are concerned that competition from biosimilars (Amgen’s Amjevita, recently approved by FDA, and Boehringer Ingelheim’s BI 695501) could blow a huge hole in the company’s revenue. Investors rightly see that AbbVie has a dilemma because the company can generate plenty of cash to sustain the dividend growth (the current dividend yield is 4.59%) from the sale of Humira. However, shareholders should not see Amgen ( AMGN ) and Boehringer Ingelheim’s products as a threat to the company’s revenues because the two medications are ‘biosimilar’ to Humira and not ‘interchangeable products’. Being a biosimilar product, it will take some time before the competing medications become marketable products that may subtract from AbbVie’s Humira market share. Furthermore, AbbVie CEO Rick Gonzalez has promised that the company can prevent ‘biosimilar’ competition until 2022.

For the original version including any supplementary images or video, visit

In.ress..f you have a known systemic condition that may be contributing your uveitis, your doctor will treat that as well. If you take steroids for a long time, you may have side effects, like cataracts, stomach ulcers, bone thinning called osteoporosis, diabetes, and weight gain. shied received a Bachelor of Science degree with donors from the University of Notre Dame. Eye specialists may describe the disease more specifically as: Anterior uveitis – the most common form of uveitis, occurs in young to middle-aged people and accounts for 75% of cases. Left alone, it can turn into serious eyesight troubles, like glaucoma or cataracts . Try retain MD About half of all uveitis cases — with most occurring in the anterior urea — don’t have an obvious cause. Vitamin C supplements may interact with other medications, including chemotherapy drugs, oestrogen, warfarin Coumadin, and others. Duane’s Ophthalmology . 2013 ed. What can I do to protect my sight? currently practices at One to One Eye Care in San Diego, A. It is often called choroditis or chorioretinitis.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>